DEFENCE TO PARTICIPATE IN THE ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING IN TORONTO ON 11 JUNE 2024

CSE: DTC Frankfurt Stock Exchange: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE TO PARTICIPATE IN THE ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING IN TORONTO ON 11 JUNE 2024

Vancouver, British Columbia, Canada, June 10, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”) (CSE: DTC, OTCQB: DTCFF, Frankfurt Stock Exchange: DTC), a Canadian biopharmaceutical company developing novel immuno-oncology therapeutics and drug delivery technologies, is pleased to announce its participation in the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”) Annual Meeting on June 11, 2024 at the Metro Toronto Convention Centre.

SNMMI is a non-profit scientific professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI aims to take a leading position in the unification, advancement and optimization of molecular imaging and radiotherapy to improve human health. With 13,000 members worldwide, SNMMI represents the experts in nuclear medicine and molecular imaging, all of whom are committed to the advancement of the field. SNMMI’s Annual Meeting is considered the premier educational, scientific, research and networking event for nuclear medicine and molecular imaging. The event enables physicians, technicians, pharmacists, laboratory personnel and scientists to gain a comprehensive overview of the latest research activities and developments in the field, as well as providing insights into practical applications for clinical practice. SNMMI’s meeting is the world’s most important conference for radiotherapy and molecular imaging, bringing together the most renowned leading companies.

In collaboration with Orano Support SAS, Defence is developing a novel radioimmunoconjugate (“RIC?) called AccuTRIC^TMwhich AccuTOX^® of Defence and leads to increased efficacy in fighting difficult to treat cancers. The aim of this project is to develop the next generation of RIC by leveraging the therapeutic dependence of Auger electron emitters (AE emitters) closer to DNA in combination with Accum^®Defence’s technology is used to create a nuclear accumulation. AE emitters are radionuclides that are very promising for radiotherapy due to their very short range, which reduces radiotoxicity for healthy tissue. Accum^® can overcome the main limitations of RIC – endosomal sequestration and poor nuclear accumulation – by disrupting the endosome membrane without affecting the plasma membrane or the specificity of monoclonal antibodies (mAbs) Defence has a variety of Accum^®-Variants with different biochemical properties and activities such as charge, hydrophobicity and cytotoxicity have been developed. One of these molecules is AccuTOX^®Defence’s lead candidate. At AccuTRIC^TM It is the combination of the synergistic activity of AccuTOX^® and the radiotherapeutic potential of Auger electrons (AE). Defence’s goal is to use AccuTRIC^TM to effectively combat difficult-to-treat cancers. This opens up the potential for a new cancer therapy market based on a very promising radiotherapeutic agent using AE emitter radionuclides.

About Defence:

Defence Therapeutics is a publicly traded clinical-stage biotech company working to develop the next generation of vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics’ platform is the ACCUM^®-Technology that enables precise delivery of vaccine antigens or ADCs in intact form to the target cells. As a result, improved efficiency and effectiveness against serious diseases such as cancer and infectious diseases can be achieved.

For further information please contact:

Sebastien Plouffe, President, CEO and Director

Phone: (514) 947-2272

[email protected]

www.defencetherapeutics.com

Note regarding forward-looking statements

This press release contains certain statements that may be classified as “forward-looking statements.” Except for statements of historical fact, all statements in this release that address events or developments that the Company expects to occur are forward-looking statements. Forward-looking statements that are not historical facts generally, but not always, can be identified by terminology such as “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “forecasts,” “possible” and similar expressions or statements that certain events or conditions “will,” “would,” “could,” “might” or “will occur.” or “should?”. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and actual results may differ materially from those expressed in such forward-looking statements. Factors that could cause actual results to differ materially from those expressed in the forward-looking statements include actions by regulatory authorities, market prices and the continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that such statements are not guarantees of future performance and actual results or developments may differ materially from those expressed in such forward-looking statements. The forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management as of the date the statements are made. Except as required by applicable stock exchange laws, the Company undertakes no obligation to update these forward-looking statements in the event of changes in management’s beliefs, estimates or opinions or in other factors.

Neither the Canadian Securities Exchange (CSE) nor its Regulatory Authority (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.